leukotriene

(redirected from Leukotriene antagonists)
Also found in: Dictionary, Encyclopedia.
Related to Leukotriene antagonists: Leukotriene receptor antagonist

leukotriene

 [loo″ko-tri´ēn]
any of a group of compounds derived from unsaturated fatty acids, primarily arachidonic acid, that are extremely potent mediators of immediate hypersensitivity reactions and inflammation, producing smooth muscle contraction, especially bronchoconstriction, increased vascular permeability, and migration of leukocytes to areas of inflammation. Certain leukotrienes are collectively known as SRS-A (slow reacting substance of anaphylaxis), the name given to their potent bronchoconstrictor activity 30 years before their structure was elucidated; they also cause leakage of fluid and proteins from the microvasculature.

leukotriene

/leu·ko·tri·ene/ (-tri´ēn) any of a group of biologically active compounds derived from arachidonic acid that function as regulators of allergic and inflammatory reactions. They are identified by the letters A, B, C, D, and E, with subscript numerals indicating the number of double bonds in each molecule.

leukotriene

(lo͞o′kə-trī′ēn)
n.
Any of several lipid compounds that contain 20 carbon atoms, are related to prostaglandins, and mediate the inflammatory response.

leukotriene

substance formed from arachidonic acid which participates in inflammatory reactions, probably as leukotoxin. May act as a slow-reacting substance in anaphylaxis.
References in periodicals archive ?
Management of exerciseinduced bronchospasm in children: the role of leukotriene antagonists.
D] Do not commence leukotriene antagonists during pregnancy.
Leukotriene antagonists as well as cycloxygenase inhibitors (cox 2 inhibitors) are two classes of drugs recently synthesized from years of analyzing the exact participants in the inflammation cascade (see Figure 1).
LEUKOTRIENE ANTAGONISTS Mediators other than histamine, including leukotrienes, are involved in the wheal-and-flare urticarial response, so one of the leukotriene antagonists used in asthma may be of benefit.
Further research comparing inhaled corticosteroids with leukotriene antagonists also would be beneficial in supporting the use of leukotriene antagonists as either alternative or add-on therapy in the treatment of chronic asthma.
In this research, Frost & Sullivan's expert analysts thoroughly examine the following markets: short acting beta 2 agonists, inhaled corticosteroids, combination therapies and leukotriene antagonists.
1,2) Additional features of the leukotriene antagonists are that they are given orally, thus avoiding any potential patient adherence problems with the use of inhaler devices, but also providing systemic activity and hence suppressing inflammation throughout the airway, including inflammation in the smaller airways.
Furthermore, studies have found that patients never refill 40% of prescriptions for leukotriene antagonists, 60% of prescriptions for long-acting [beta.
They used inhaled corticosteroids but nut theophylline, nasal steroids, leukotriene antagonists, or [H.
Currently the treatment of asthma/COPD favors the use of beta-2 agonists and inhaled corticosteroids, with leukotriene antagonists and anticholinergics being positioned as additional therapies in either pediatric or last-line patients.
The leukotriene antagonists are usually well tolerated and in some asthmatics can provide significant benefit.
All of them were using inhaled corticosteroids, but none used theophylline, nasal steroids, leukotriene antagonists, or [H.